share_log

Baird Initiates Coverage On Xenon Pharmaceuticals With Outperform Rating, Announces Price Target of $63

Baird Initiates Coverage On Xenon Pharmaceuticals With Outperform Rating, Announces Price Target of $63

貝爾德以跑贏大盤的評級啓動對Xenon Pharmicals的報道,宣佈目標股價爲63美元
Benzinga ·  2023/12/08 05:29

Baird analyst Brian Skorney initiates coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform rating and announces Price Target of $63.

貝爾德分析師布萊恩·斯科尼開始對Xenon Pharmicals(納斯達克股票代碼:XENE)進行報道,評級爲跑贏大盤,並宣佈目標股價爲63美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論